Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Valproic acid and secondary hyperammonemia.

S Rawat, W J Borkowski, H M Swick

    Neurology
    |September 1, 1981
    PubMed
    Summary
    This summary is machine-generated.

    Valproic acid (VPA) can cause severe hyperammonemia, a rare side effect. This condition is reversible and distinct from VPA-induced liver damage.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Conformance to the National List of Essential Medicines 2022 in a government tertiary care hospital.

    Journal of healthcare quality research·2025
    Same author

    Effects of aircraft operating fluids and environmental thermal fatigue on fly ash and steel slag based cementitious composites.

    Scientific reports·2024
    Same author

    Even Mists Have Silver Linings: Promoting LGBTQ+ Acceptance and Solidarity through Community-Based Theatre in India.

    Public health·2021
    Same author

    Development of recombinant nonstructural 1 protein based indirect enzyme linked immunosorbent assay for sero-surveillance of Japanese encephalitis in swine.

    Journal of virological methods·2019
    Same author

    Weekly versus Three-Weekly Cisplatin-based Concurrent Chemoradiotherapy as definitive treatment in Head and Neck Cancer- Where do we stand?

    The Gulf journal of oncology·2016
    Same author

    Genome-wide association analysis identifies genetic variations in subjects with myalgic encephalomyelitis/chronic fatigue syndrome.

    Translational psychiatry·2016
    Same journal

    Teaching Video NeuroImage: Tardive Blepharoclonus.

    Neurology·2026
    Same journal

    Teaching NeuroImage: Latent Axonal Degeneration in Patient With Anterior Circulation Stroke.

    Neurology·2026
    Same journal

    Incidental DWI-Positive Lesions in 2 Cohorts of CAA and CADASIL: Prevalence, Distribution, and Associations With Clinical Variables.

    Neurology·2026
    Same journal

    Alpha-Synuclein Seed Amplification Assay in CSF, Skin, and Submandibular Gland From Incidental Lewy Body Disease and Parkinson Disease.

    Neurology·2026
    Same journal

    Digital Semiology.

    Neurology·2026
    Same journal

    Early Cerebral Edema Subtypes and Functional Outcome in Patients With Cerebral Venous Thrombosis: Insights From the CLOT-VENUS Registry.

    Neurology·2026
    See all related articles

    Area of Science:

    • Neurology
    • Clinical Pharmacology
    • Biochemistry

    Background:

    • Valproic acid (VPA) is a broad-spectrum antiepileptic drug used for managing complex seizures.
    • Concomitant use of clonazepam and ethosuximide is common in refractory epilepsy cases.

    Observation:

    • An 11-year-old girl on VPA, clonazepam, and ethosuximide developed significant hyperammonemia.
    • Hyperammonemia worsened with protein intake and resolved upon VPA discontinuation.
    • No concurrent elevation in liver enzymes (transaminases) or bilirubin was noted.

    Findings:

    • Valproic acid can induce isolated hyperammonemia as an infrequent, reversible adverse effect.
    • The onset of hyperammonemia can be rapid following VPA initiation.
    • This specific side effect appears mechanistically distinct from VPA-induced hepatotoxicity.

    Related Experiment Videos

    Implications:

    • Clinicians should monitor for hyperammonemia in patients initiating VPA, especially those with complex seizures.
    • Prompt recognition and VPA withdrawal can reverse hyperammonemia, preventing potential complications.
    • Distinguishing VPA-induced hyperammonemia from other causes of elevated ammonia is crucial for appropriate management.